Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Stavudine

FDA-approved product (capsule, oral), marketed as Stavudine, Zerit, Zerit Xr.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
0 of 4

Chemical structure

Chemical structure of Stavudine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF04

Repurposing investigation

No supported pathogen reaches ≥40% AI-predicted activity for Stavudine, so it is not among the repurposing candidates. Its predictions are shown below.

AI-predicted activity

AI prediction · nothing measured
  • MRSA13.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli14.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae13.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis22.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Stavudine in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Stavudine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

    NCT06337032 · start 2024-08-27

    Registered record
    Registry ID
    NCT06337032
    Conditions
    HIV-1-infection
    Interventions
    F/TAF (High Dose Tablet); F/TAF (Low Dose Tablet); F/TAF (Lowest Dose Tablet); F/TAF (High Dose TOS); F/TAF (Low Dose TOS); F/TAF (Lowest Dose TOS); E/C/F/TAF; E/C/F/TAF (Low Dose); Cobicistat (High Dose); Cobicistat (Low Dose); Cobicistat (TOS); B/F/TAF (High Dose); B/F/TAF (Low Dose); B/F/TAF (High Dose TOS); B/F/TAF (Low Dose TOS); B/F/TAF (Lowest Dose TOS); 3rd ARV Agent; Nucleos(t)ide reverse transcriptase inhibitors (NRTI); ATV; DRV; Lopinavir Boosted with ritonavir (LPV/r)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-08-27
    Completion
    2034-03
    Enrolment
    350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1-infection
    InterventionF/TAF (High Dose Tablet); F/TAF (Low Dose Tablet); F/TAF (Lowest Dose Tablet); F/TAF (High Dose TOS) +17 more
    PhasePhase 4
    Registry statusRecruiting

  • Impact on T Cell Immune Activation and Inflammation of Triptolide Woldifii in HIV-infected Immunological Non-responders

    NCT01817283 · start 2013-01

    Registered record
    Registry ID
    NCT01817283
    Conditions
    HIV
    Interventions
    Triptolide; cART; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Unknown
    Start
    2013-01
    Completion
    2015-03
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionTriptolide; cART; placebo
    PhasePhase 1 / Phase 2
    Registry statusUnknown

  • Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy

    NCT01694017 · start 2012-11

    Registered record
    Registry ID
    NCT01694017
    Conditions
    HIV
    Interventions
    Tenofovir; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-11
    Completion
    2014-08
    Enrolment
    68

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionTenofovir; Zidovudine
    PhasePhase 4
    Registry statusCompleted

  • Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF

    NCT01252940 · start 2010-11

    Registered record
    Registry ID
    NCT01252940
    Conditions
    HIV-1 Infection
    Interventions
    FTC/RPV/TDF; PI; RTV; NRTIs
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-11
    Completion
    2014-10
    Enrolment
    482

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionFTC/RPV/TDF; PI; RTV; NRTIs
    PhasePhase 3
    Registry statusCompleted

  • HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children

    NCT00978068 · start 2009-09

    Registered record
    Registry ID
    NCT00978068
    Conditions
    Malaria; HIV Infections
    Interventions
    Lopinavir/Ritonavir (LPV/r); Nevirapine (NVP); Efavirenz (EFV); 2 nucleoside reverse transcriptase inhibitor (NRTI)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-09
    Completion
    2013-01
    Enrolment
    176

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria; HIV Infections
    InterventionLopinavir/Ritonavir (LPV/r); Nevirapine (NVP); Efavirenz (EFV); 2 nucleoside reverse transcriptase inhibitor (NRTI)
    PhasePhase 3
    Registry statusCompleted

  • Study on the Antiviral Therapy and Immune Reconstitution of Chinese HIV/AIDS Patients

    NCT00872417 · start 2009-03

    Registered record
    Registry ID
    NCT00872417
    Conditions
    Acquired Immune Deficiency Syndrome; HIV Infections
    Interventions
    first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT); second line ARV therapy (3TC+TDF+LPV/RTV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2009-03
    Completion
    2010-12
    Enrolment
    750

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immune Deficiency Syndrome; HIV Infections
    Interventionfirst line ARV (3TC+NVP+D4T or 3TC+NVP+AZT); second line ARV therapy (3TC+TDF+LPV/RTV)
    PhasePhase 4
    Registry statusUnknown

  • Acquired Immunodeficiency Syndrome(AIDS) and Tuberculosis(Tb) Co-infection Treatment Strategies Study of China.

    NCT01344148 · start 2009-02

    Registered record
    Registry ID
    NCT01344148
    Conditions
    AIDS
    Interventions
    INH RIF Rifb PZA EMB AZT 3TC D4T EFV
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2009-02
    Completion
    2013-06
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAIDS
    InterventionINH RIF Rifb PZA EMB AZT 3TC D4T EFV
    PhaseNot applicable
    Registry statusUnknown

  • Drug Interaction Between Coartem® and Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients

    NCT00620438 · start 2008-02

    Registered record
    Registry ID
    NCT00620438
    Conditions
    HIV Infections; Tuberculosis
    Interventions
    Lumefantrine-artemether and nevirapine; lumefantrine-artemether and efavirenz; Lumefantrine-artemether and rifampicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2008-02
    Completion
    2011-07
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Tuberculosis
    InterventionLumefantrine-artemether and nevirapine; lumefantrine-artemether and efavirenz; Lumefantrine-artemether and rifampicin
    PhasePhase 4
    Registry statusUnknown

  • Comparison of Nevirapine and Efavirenz for the Treatment of HIV-TB Co-infected Patients (ANRS 12146 CARINEMO)

    NCT00495326 · start 2007-12

    Registered record
    Registry ID
    NCT00495326
    Conditions
    Tuberculosis; Aids; Hiv Infections
    Interventions
    Nevirapine based therapy; Efavirenz based therapy; Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2007-12
    Completion
    2011-04
    Enrolment
    570

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTuberculosis; Aids; Hiv Infections
    InterventionNevirapine based therapy; Efavirenz based therapy; Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Safety and Efficacy of Switching From Stavudine or Zidovudine to Tenofovir DF in HIV-1 Infected Children

    NCT00528957 · start 2006-12-28

    Registered record
    Registry ID
    NCT00528957
    Conditions
    HIV Infections
    Interventions
    Tenofovir DF; Zidovudine; Stavudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-12-28
    Completion
    2017-08-16
    Enrolment
    97

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTenofovir DF; Zidovudine; Stavudine
    PhasePhase 3
    Registry statusCompleted

  • Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort

    NCT00618176 · start 2005-01

    Registered record
    Registry ID
    NCT00618176
    Conditions
    HIV Infections
    Interventions
    Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP); Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP); Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2005-01
    Completion
    Not recorded
    Enrolment
    198

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionZidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP); Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP); Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)
    PhasePhase 4
    Registry statusCompleted

  • Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients

    NCT00084253 · start 2004-06

    Registered record
    Registry ID
    NCT00084253
    Conditions
    HIV Infections
    Interventions
    Atazanavir/ Stavidine / Lamivudine; Atazanavir-Ritonavir/ Stavidine / Lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2004-06
    Completion
    Not recorded
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAtazanavir/ Stavidine / Lamivudine; Atazanavir-Ritonavir/ Stavidine / Lamivudine
    PhasePhase 4
    Registry statusCompleted

  • A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected Patients

    NCT00002207 · start 2004-02

    Registered record
    Registry ID
    NCT00002207
    Conditions
    HIV Infections
    Interventions
    Stavudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-02
    Completion
    2004-02
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionStavudine; Didanosine
    PhaseNot applicable
    Registry statusCompleted

  • Long Term Treatment Interruptions

    NCT00433056 · start 2004-01

    Registered record
    Registry ID
    NCT00433056
    Conditions
    HIV Infections; AIDS
    Interventions
    STI; stable HAART
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-01
    Completion
    Not recorded
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; AIDS
    InterventionSTI; stable HAART
    PhasePhase 3
    Registry statusCompleted

  • A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea

    NCT00650637 · start 2003-01

    Registered record
    Registry ID
    NCT00650637
    Conditions
    Diarrhea
    Interventions
    Calcium Carbonate; nelfinavir; lamivudine; loperamide; Calcium carbonate not administered; nelfinavir; lamivudine + zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2003-01
    Completion
    2003-08
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiarrhea
    InterventionCalcium Carbonate; nelfinavir; lamivudine; loperamide +3 more
    PhasePhase 3
    Registry statusTerminated